alk-abello.comALK | Allergy solutions for life

Your allergy What is allergy House dust mite allergy Pollen allergy Living with allergy Socio-economic impact What is allergic asthma How is allergy diagnosed Treating allergy Our solutions Consumer healthcare Diagnostics Allergy vaccines Production Emergency medicine Our science Allergy immunotherapy Pipeline Clinical trials Clinical data sharing Our company Newsroom Stories Privacy Global presence Organisation History Owners Sustainability Investors Overview Financial reporting Risk management Reporting standards Auditors Governance IR policy Management Board of directors Annual general meeting Annual general meeting (DK) News & Events Company releases Company releases (DK) Webcasts & presentations Investor calendar The Share Dividend history Analyst coverage Analyst estimates Shareholder information Authorizations ADR Programme Contact IR Management Board of directors AGM AGM (DK) Careers Working at ALK Vacant positions Cultural Beliefs Select country Fulltext search Search ALK Allergy solutions for life Read about ALK's allergy solutions Take back control More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing. Watch the video News See all Post date 05/10/2021 Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff Read more Post date 05/05/2021 Three-month interim report (Q1) 2021 Read more Post date 04/28/2021 Release date of three-month interim report (Q1) 2021 for ALK and audio cast Read more Post date 04/19/2021 ALK gains paediatric approval for its ragweed SLIT-tablet in the USA Read more Post date 03/26/2021 Grant of share options and performance shares to members of the Board of Management and key employees Read more Post date 03/18/2021 Annual General Meeting in ALK-Abelló A/S held on 18 March 2021 Read more Post date 03/10/2021 Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff Read more Post date 03/03/2021 Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff Read more Post date 03/02/2021 Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff Read more ALK supports eSOSA 2021 The SOSA programme includes the most recent updates in the field of specific allergy. The scientific programme for SOSA is developed by a pre-eminent International Scientific Committee and involves a faculty of around 35 distinguished speakers from the allergy scientific community. In 2021, to adapt to the COVID-19 limitations, SOSA will be held as a virtual event: eSOSA 2021. Register here Strategy update: Focus areas during 2021-23 Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability. Read more about ALK's strategy update ALK rewards excellence in allergy The Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy. How to apply Seasonal allergy symptoms can be confused with COVID-19 Therefore allergy symptoms should be kept under the best possible control. Watch Dr Glenis Scadding's expert advise in respect of seasonal allergies and COVID-19. For further information visit EUFOREA seasonal_allergic_rhinitis_in_relation_to_covid-19 Video of seasonal_allergic_rhinitis_in_relation_to_covid-19 ALK in brief Allergy at a glance Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world. Read more about allergy and its symptoms Our solutions By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage. Read more about ALK's allergy solutions Our heritage Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments. Read more about ALK's history Our responsibility We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments. Read more about sustainability Select Country Menu Change Country Quick Links Contact us News Media Vacant jobs Products ALK Footer Copyright Text ALK-Abelló A/S ∙ Bøge Allé 6-8 (Visiting Address: Bøge Allé 1) ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Privacy notice | Cookie notice | Legal disclaimer © 2018 ALK ∙ All rights reserved...